drugset / Trial / NCT05738382
Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To explore the optimal effective daily dose of BG2109 to suppress premature luteinizing hormone (LH) surge during COH in female subjects undergoing ART procedures.
Timeline
- Start
- 2023-08
- Primary completion
- 2024-06
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BG2109 | Unknown | 75 mg | Oral |
| Subject | BG2109 | Unknown | 150 mg | Oral |
| Subject | BG2109 | Unknown | 200 mg | Oral |
| Comparator | Cetrorelix | Other / unclassified | 0.25 mg | Subcutaneous |
Indications
No indication recorded.